gip glp 1 glucagon agonists This review summarizes how GLP-1 and dual GIP/GLP-1 receptor act at the cellular level and their therapeutic applications in metabolic diseases like type 2 diabetes and obesity, highlighting advances in incretin-based Free Comparison Chart: GLP-1 and

Aids sustainable weight management

In 2025 we saw label expansions for semaglutide and tirzepatide, underscoring a trend toward whole-body health

We also present practical implications of these glucose-lowering agents for reducing the risk of adverse cardiovascular events and progressive renal comorbidity in patients with T2D and CVD.

What impact will they have over the next 5 years?

Researchers found that people taking these medications were less likely to develop substance use disorders involving alcohol, nicotine, cannabis, cocaine, opioids, and other drugs, while those already struggling with addiction experienced fewer overdoses, hospitalizations, emergency visits, and drug-related deaths.